Screening for Early Adrenal Reserve Impairment: Clinical Implications and Evidence-Based Approaches

Abstract

Early adrenal reserve impairment is an under-recognized but clinically significant phenomenon that can predispose patients to adrenal insufficiency, particularly under physiological stress. Timely identification and intervention are paramount to prevent life-threatening adrenal crises. This review synthesizes the latest evidence, mechanisms, and clinical considerations for screening early adrenal reserve impairment, highlighting epidemiological data, pathophysiological underpinnings, risk factors, diagnostic modalities, treatment strategies, recent advances, and guideline recommendations. The article aims to equip clinicians with a comprehensive understanding of this condition and practical recommendations for optimal patient care.

Introduction

Adrenal reserve refers to the capacity of the adrenal cortex to mount an adequate hormonal response to stress. Impairment in this reserve, even before overt adrenal insufficiency manifests, can have profound consequences, especially in critically ill or high-risk populations. Screening for early adrenal reserve impairment has become an area of growing clinical interest, as recent studies underscore the morbidity associated with delayed recognition. This review addresses the importance of early detection, explores various screening methodologies, and contextualizes emerging evidence within contemporary clinical practice.

Epidemiology / Disease Burden

The prevalence of adrenal reserve impairment varies by population and comorbidity. Studies estimate that up to 15% of critically ill patients may develop some form of adrenal dysfunction, with higher rates observed among those with sepsis, chronic steroid exposure, or autoimmune disorders. Community-based surveys suggest that subclinical adrenal impairment may affect 2-5% of individuals with chronic illnesses. The burden is disproportionately higher in certain demographics, such as individuals with pituitary disorders, those undergoing prolonged glucocorticoid therapy, and transplant recipients. Importantly, adrenal reserve impairment is often underdiagnosed due to its nonspecific presentation and the limitations of conventional testing.

Pathophysiology

The adrenal cortex is responsible for synthesizing glucocorticoids, mineralocorticoids, and adrenal androgens. Early impairment of adrenal reserve typically results from disruptions in the hypothalamic-pituitary-adrenal (HPA) axis, direct adrenal injury, or receptor-level resistance. Common mechanisms include autoimmune destruction (Addison’s disease), suppression of ACTH secretion (secondary adrenal insufficiency), or iatrogenic suppression from exogenous steroid use. At the cellular level, chronic inflammation, ischemia, and hemorrhage can induce apoptosis of adrenocortical cells, reducing the gland’s ability to respond to ACTH stimulation. Molecular alterations in steroidogenic enzymes and ACTH receptor function also contribute to early reserve impairment.

Risk Factors

Several risk factors predispose individuals to early adrenal reserve impairment. Chronic glucocorticoid therapy remains the most significant, with the risk proportional to dose and duration. Other notable risk factors include autoimmune polyendocrine syndromes, pituitary or hypothalamic disorders, infections (notably tuberculosis and HIV), infiltrative diseases (such as sarcoidosis), adrenal hemorrhage, and malignancy. Patients with chronic kidney disease, critical illness, or major surgery also exhibit higher incidence, likely due to sustained physiologic stress and HPA axis dysregulation. Awareness of these risk factors is crucial for targeted screening.

Clinical Features

Early adrenal reserve impairment often presents insidiously. Symptoms are nonspecific, such as fatigue, myalgia, hypotension, gastrointestinal disturbances, and mood changes. In the perioperative or critical care setting, impaired adrenal reserve may manifest as refractory hypotension, unexplained hypoglycemia, or persistent hyponatremia. Importantly, these symptoms may precede overt adrenal crisis, highlighting the need for high clinical suspicion in at-risk populations. Subtle laboratory abnormalities—such as borderline low cortisol or elevated ACTH—may be the only early clues.

Diagnosis

Screening for early adrenal reserve impairment relies on dynamic testing. Baseline morning serum cortisol levels can be informative, but are insufficiently sensitive or specific. The standard short Synacthen (cosyntropin) stimulation test remains the gold standard, with impaired response indicating reduced adrenal reserve. In select cases, the insulin tolerance test (ITT) or metyrapone test may be employed, particularly when pituitary dysfunction is suspected. Recent advances in assay sensitivity, including liquid chromatography-tandem mass spectrometry (LC-MS/MS), have improved diagnostic accuracy. Interpreting results requires consideration of clinical context, as acute illness can alter cortisol dynamics.

Treatment & Management

Management of early adrenal reserve impairment focuses on addressing underlying etiologies, optimizing steroid replacement when indicated, and patient education. In individuals with biochemical evidence of impaired reserve but without overt insufficiency, stress dosing with hydrocortisone may be warranted during illness or surgery. Chronic low-dose corticosteroid therapy is reserved for those with persistent symptoms or recurrent crises. Regular monitoring and titration based on clinical status is essential, with attention to minimizing steroid-related side effects. Patient counseling regarding sick-day rules and emergency steroid administration is critical to prevent adrenal crisis.

Recent Advances / Emerging Therapies

Recent research has yielded promising developments in both diagnostic and therapeutic domains. Ultra-sensitive cortisol assays, salivary cortisol measurement, and novel ACTH analogues are enhancing early detection. The use of modified-release hydrocortisone preparations aims to mimic physiological circadian rhythm, potentially improving outcomes and quality of life. Advances in immunotherapy for autoimmune adrenalitis and regenerative approaches targeting adrenal stem cells are under investigation, offering potential for disease modification. Telemedicine and digital health platforms are also facilitating remote monitoring and patient education.

Guideline Recommendations

Current guidelines from the Endocrine Society and European Society of Endocrinology recommend targeted screening for adrenal reserve impairment in high-risk groups, such as patients on chronic glucocorticoids, those with pituitary disease, or unexplained symptoms suggestive of adrenal dysfunction. Dynamic testing is preferred over static cortisol measurements, and clinicians are advised to interpret results within the full clinical context. Guidelines emphasize patient education, sick-day management, and regular follow-up, as well as multidisciplinary collaboration for complex cases.

Conclusion

Screening for early adrenal reserve impairment is essential for the prevention of adrenal crises and the optimization of patient outcomes, particularly in high-risk populations. Advances in diagnostic technology and a better understanding of risk factors and pathophysiology are enabling earlier and more accurate detection. Clinicians must maintain a high index of suspicion, utilize evidence-based screening protocols, and individualize management strategies. Ongoing research and guideline updates will continue to refine best practices and improve care for patients at risk of adrenal dysfunction.